Publications by authors named "G M Baldi"

This report, the second of its kind from ASINA project, aims at providing a roadmap with quantitative metrics for Safe(r) and (more) Sustainable by Design (SSbD) solutions for titanium dioxide (TiO) nanomaterials (NMs). We begin with a brief description of ASINA's methodology across the product lifecycle, highlighting the quantitative elements, such as the Key Performance Indicators (KPIs). We then propose a decision support tool for implementing SSbD objectives across various dimensions-functionality, cost, environment, and human health safety.

View Article and Find Full Text PDF

Epithelioid sarcoma (ES) is a rare tumor hallmarked by the loss of INI1/SMARCB1 expression. Apart from this alteration, little is known about the biology of ES. Despite recent advances in treatment, the prognosis of ES remains unsatisfactory.

View Article and Find Full Text PDF

The aim of the study was to report the outcome of primary localized low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid LGFMS/SEF (H-LGFMS/SEF). Patients with primary localized LGFMS, SEF, or H-LGFMS/SEF, surgically treated with curative intent from January 2000 to September 2022, were enrolled from 14 countries and 27 institutions. Pathologic inclusion criteria were predefined by expert pathologists.

View Article and Find Full Text PDF
Article Synopsis
  • There was an error in the original publication that needs to be addressed.
  • The correction is important for ensuring accurate information.
  • Readers should refer to the updated version to get the correct details.
View Article and Find Full Text PDF
Article Synopsis
  • A retrospective study by the Ultra-Rare Sarcoma Working Group analyzed data from 101 patients with metastatic low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid (H)-LGFMS/SEF across 28 centers from January 2000 to September 2022.
  • The study measured progression-free survival (PFS) from the detection of metastasis and after starting treatment, revealing varying effectiveness among the different sarcoma types and treatments.
  • Findings showed that metastatic LGFMS and SEF had distinct survival outcomes, with systemic treatments showing limited effectiveness, suggesting a need for new therapeutic options in future research.
View Article and Find Full Text PDF